Concise Review: A Safety Assessment of Adipose-Derived Cell Therapy in Clinical Trials: A Systematic Review of Reported Adverse Events: A Safety Assessment of Adipose-Derived Cell Therapy in Clinical Trials:A Systematic Review of Reported Adverse Events
Uloženo v:
| Název: | Concise Review: A Safety Assessment of Adipose-Derived Cell Therapy in Clinical Trials: A Systematic Review of Reported Adverse Events: A Safety Assessment of Adipose-Derived Cell Therapy in Clinical Trials:A Systematic Review of Reported Adverse Events |
|---|---|
| Autoři: | Navid Mohamadpour Toyserkani, Charlotte Harken Jensen, Mads Gustaf Jørgensen, Søren P. Sheikh, Siavosh Tabatabaeifar, Jens Ahm Sørensen |
| Zdroj: | Stem Cells Transl Med Toyserkani, N M, Jørgensen, M G, Tabatabaeifar, S, Jensen, C H, Sheikh, S P & Sørensen, J A 2017, ' Concise Review : A Safety Assessment of Adipose-Derived Cell Therapy in Clinical Trials:A Systematic Review of Reported Adverse Events ', Stem Cells Translational Medicine, vol. 6, no. 9, pp. 1786–1794 . https://doi.org/10.1002/sctm.17-0031 |
| Informace o vydavateli: | Oxford University Press (OUP), 2017. |
| Rok vydání: | 2017 |
| Témata: | 0301 basic medicine, 0303 health sciences, Complications, Stromal vascular fraction, Review, Mesenchymal Stem Cell Transplantation, 3. Good health, 03 medical and health sciences, Mesenchymal Stem Cell Transplantation/adverse effects, Translational Research Articles and Reviews, Adipose Tissue, Adverse events, Journal Article, Humans, Adipose Tissue/cytology, Safety, Adipose-derived stromal cells |
| Popis: | The popularity of adipose-derived cell therapy has increased over the last decade, and the number of studies published annually is growing. However, concerns regarding safety in the setting of previous malignancy or the use of allogeneic cells have been raised. We therefore aimed to systematically review all clinical studies using adipose-derived cell therapy to identify reported adverse events with a special focus on risk of thromboembolic, immunological, and oncological safety concerns. Our systematic search resulted in 70 included studies involving more than 1,400 patients that were treated with adipose-derived cell therapy. Safety assessment method was not described in 32 of the included studies. For studies involving systemic or cardiac administration, one case of pulmonary thromboembolism and cases of both myocardial and cerebral infarctions were described. In the setting of allogeneic cell therapy studies, where the production of specific antibodies toward donor cells was examined, it was noted that 19%–34% of patients develop antibodies, but the consequence of this is unknown. With regard to oncological safety, only one case of breast cancer recurrence was identified out of 121 patients. Adipose-derived cell therapy has so far shown a favorable safety profile, but safety assessment description has, in general, been of poor quality, and only adverse events that are looked for will be found. We encourage future studies to maintain a strong focus on the safety profile of cell therapy, so its safeness can be confirmed. |
| Druh dokumentu: | Article Other literature type |
| Popis souboru: | application/pdf |
| Jazyk: | English |
| ISSN: | 2157-6580 2157-6564 |
| DOI: | 10.1002/sctm.17-0031 |
| Přístupová URL adresa: | https://pubmed.ncbi.nlm.nih.gov/28722289 https://stemcellsjournals.onlinelibrary.wiley.com/doi/pdf/10.1002/sctm.17-0031%4010.1002/%28ISSN%291549-4918.adipose-tissue-collection https://portal.findresearcher.sdu.dk/da/publications/concise-review-a-safety-assessment-of-adipose-derived-cell-therap https://findresearcher.sdu.dk:8443/ws/files/126117400/Concise_Review.pdf https://stemcellsjournals.onlinelibrary.wiley.com/doi/10.1002/sctm.17-0031 https://core.ac.uk/display/84686978 https://www.onlinelibrary.wiley.com/doi/10.1002/sctm.17-0031 https://portal.findresearcher.sdu.dk/da/publications/4aad3a68-0ef7-4c5b-976b-2b7c7215a37a https://doi.org/10.1002/sctm.17-0031 https://findresearcher.sdu.dk:8443/ws/files/126117400/Concise_Review.pdf |
| Rights: | CC BY NC ND |
| Přístupové číslo: | edsair.doi.dedup.....5d6a1d03d8da3fa0314c460b6645761a |
| Databáze: | OpenAIRE |
Full Text 
Full Text Finder 
Nájsť tento článok vo Web of Science | Abstrakt: | The popularity of adipose-derived cell therapy has increased over the last decade, and the number of studies published annually is growing. However, concerns regarding safety in the setting of previous malignancy or the use of allogeneic cells have been raised. We therefore aimed to systematically review all clinical studies using adipose-derived cell therapy to identify reported adverse events with a special focus on risk of thromboembolic, immunological, and oncological safety concerns. Our systematic search resulted in 70 included studies involving more than 1,400 patients that were treated with adipose-derived cell therapy. Safety assessment method was not described in 32 of the included studies. For studies involving systemic or cardiac administration, one case of pulmonary thromboembolism and cases of both myocardial and cerebral infarctions were described. In the setting of allogeneic cell therapy studies, where the production of specific antibodies toward donor cells was examined, it was noted that 19%–34% of patients develop antibodies, but the consequence of this is unknown. With regard to oncological safety, only one case of breast cancer recurrence was identified out of 121 patients. Adipose-derived cell therapy has so far shown a favorable safety profile, but safety assessment description has, in general, been of poor quality, and only adverse events that are looked for will be found. We encourage future studies to maintain a strong focus on the safety profile of cell therapy, so its safeness can be confirmed. |
|---|---|
| ISSN: | 21576580 21576564 |
| DOI: | 10.1002/sctm.17-0031 |